Skip to main content

Year: 2019

MannKind Corporation to Present at the Piper Jaffray 31st Annual Healthcare Conference

WESTLAKE VILLAGE, Calif., Nov. 29, 2019 (GLOBE NEWSWIRE) — MannKind Corporation (NASDAQ: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension, announced today that it will be featured as a presenting company at the Piper Jaffray 31st Annual Healthcare Conference on Tuesday, December 3, 2019 at 3:30 p.m. (ET) at the Lotte New York Palace in New York City. Presenting from the Company will be its Chief Executive Officer, Michael Castagna. The presentation will be webcast live. Interested parties can access a link to the live webcast of the presentation from the News & Events section of the Company’s website at http://www.mannkindcorp.com. The webcast replay will remain available for 14 days following...

Continue reading

ATW Tech Announces Revenues of $1.1M for Its Third Quarter of 2019

MONTREAL, Nov. 29, 2019 (GLOBE NEWSWIRE) — ATW Tech Inc. (the “Company” or “ATW Tech”) (TSX-V: ATW) announces today its results for the quarter ending September 30, 2019.On July 31st, 2019, the Company sold the assets of its VuduMobile division for $1,350,000. It is important for the reader to note that the results as at September 30th, 2019 include only the July 2019 results of the VuduMobile division; For its third quarter of 2019, the Company generated revenues of $1.1 million from its continuing operations.During the third quarter, for the VoxTel division, the Company focused on a partnership strategy to leverage its reputation with its operating partners and the CRTC. This approach aims to improve the Company’s performance and to achieve a positive EBITDA in 2020 in order to obtain a better valuation for ATW Tech.The Company...

Continue reading

ATW Tech annonce des revenus de 1,1M$ pour son troisième trimestre 2019

MONTRÉAL, 29 nov. 2019 (GLOBE NEWSWIRE) — ATW Tech Inc. (la « Société » ou « ATW Tech ») (TSX-V : ATW) annonce aujourd’hui ses résultats pour son trimestre se terminant le 30 septembre 2019.Le 31 juillet 2019, la Société a vendu les actifs de sa division VuduMobile pour 1 350 000 $. Il est important pour le lecteur de noter que les résultats au 30 septembre 2019 comprennent uniquement les résultats du mois de juillet 2019 de la division VuduMobile. Pour son troisième trimestre 2019, la Société a généré des revenus de ses activités poursuivies de 1,1m$;Au cours du troisième trimestre, pour la division VoxTel, la Société a mis ses efforts sur une stratégie de partenariat afin de bénéficier de sa réputation auprès de ses partenaires opérateurs et le CRTC. Cette approche vise une amélioration de son rendement et la poursuite en...

Continue reading

ContraFect to Present at the Piper Jaffray 31st Annual Healthcare Conference

YONKERS, N.Y., Nov. 29, 2019 (GLOBE NEWSWIRE) — ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announced that Roger J. Pomerantz, MD, President, Chief Executive Officer and Chairman of ContraFect, will participate in a fireside chat at the Piper Jaffray 31st Annual Healthcare Conference on Tuesday, December 3, 2019, at 12:00 PM ET in New York City.A live webcast of the presentation will be available on the Investors & Media section of the Company’s website at www.contrafect.com. The presentation will also be available as an archived webcast for a limited time. About ContraFect:ContraFect...

Continue reading

New Micro-Simulation Study in Cancer Medicine Finds Epi proColon® Provides Clinically Meaningful Reductions in Incidence and Mortality of Colorectal Cancer

– Adherence rates and screening intervals recognized as decisive elements of successful screening strategies –BERLIN, Nov. 29, 2019 (GLOBE NEWSWIRE) — Epigenomics AG (FSE: ECX, OTCQX: EPGNY; the “Company”), today reported on micro-simulation model results indicating that Epi proColon®, a colorectal cancer (CRC) screening test approved for patients who are unwilling or unable to be screened by the United States Preventive Services Task Force (USPSTF) recommended methods, provides clinically meaningful reductions in the incidence and mortality of CRC comparable to those of USPSTF currently recommended methods. The micro-simulation model, developed and validated at Harvard Medical School, evaluated the impact of adherence rates, testing intervals and clinical performance of different screening strategies on CRC incidence...

Continue reading

Foresight 4 VCT plc – Half-year report

FORESIGHT 4 VCT PLCFinancial Highlights• Diversified portfolio of 33 companies.• Net asset value per share decreased by 3.7% in the period from 67.8p at 31 March 2019 to 65.3p. Including the payment of a 4.0p dividend made on 16 August 2019, NAV per share at 30 September 2019 was 69.3p, representing a positive total return 2.2%.• The Company completed two new investments, totalling £3.6 million.• A total of £51 million was raised under the offer for subscription dated 14 June 2018, which closed on 7 June 2019.• The portfolio has seen an uplift in valuation of £4.3 million in the last six months.Chairman’s StatementI am pleased to present the Unaudited Half-Yearly Financial Report for Foresight 4 VCT plc for the period ended 30 September 2019.DIVIDENDSIn line with the Board’s objective on dividend payments, an interim dividend of...

Continue reading

ESO preliminary financial results for 10 month of 2019

Energijos Skirstymo Operatorius AB (hereinafter – ESO or the Company), identification code 304151376, registered office located at Aguonų g. 24, Vilnius, Republic of Lithuania. The total number of registered ordinary shares issued by the Company is 894 630 333; ISIN code LT0000130023.Preliminary ESO financial data for 10 months of 2019:Revenue of the electricity and natural gas distribution company ESO totaled EUR 431.3 million in 10 months of 2019 and decreased by 17.4 % compared to the same period of 2018, when it was EUR 522.1 million. Excluding the influence of the public electricity supply activity, revenue of 10 months 2019 increased by 2.4% compared to the same period of 2018, when it comprised EUR 421.1 million.The main reason of revenue increase – revenue from new customer connection due to changes of income recognition principles...

Continue reading

Preliminarūs ESO 2019 m. 10 mėnesių rezultatai

AB „Energijos skirstymo operatorius“ (toliau – ESO  ir  Bendrovė), kodas 304151376, registruotos buveinės adresas Aguonų g. 24, Vilnius. Bendras AB „Energijos skirstymo operatorius“ išleistų paprastųjų vardinių akcijų skaičius yra 894 630 333; ISIN kodas – LT0000130023.2019 metų 10 mėnesių preliminarūs ESO finansiniai duomenys:Elektros ir gamtinių dujų skirstymo bendrovės ESO pajamos per 2019 metų 10 mėnesių sudarė 431,3 mln. eurų ir buvo 17,4 proc. mažesnės nei tokiu pat metu pernai, kai jos siekė 522,1 mln. eurų. Eliminavus nebevykdomos visuomeninio tiekimo veiklos įtaką, 2019 m. 10 mėnesių pajamos yra 2,4 proc. didesnės už atitinkamo laikotarpio 2018 metų pajamas, kai jos siekė 421,1 mln. eurų.Didėjančių pajamų pagrindinės priežastis – dėl pajamų pripažinimo pagal 15-ąjį TFAS (Tarptautinį finansinės apskaitos standartą) pokyčių išaugusios...

Continue reading

AB “Linas” not audited consolidated interim information of nine months of year 2019

On November 29, 2019 AB “Linas” Board confirmed AB “Linas” consolidated interim financial reports of nine months of year 2019 which are not checked by the auditors and prepared acc.to International financial accountability standards accepted by EU.The sales incomes for January-September of year 2019 of AB “Linas” Group of companies made 9.9 mln EUR. During the same period of year 2018 sales incomes were 9.2 mln EUR.Profit before taxation of the nine months of year 2019 AB “Linas” group of companies – 0.13 mln EUR and result of Group of the nine months of year 2018 was profit 0.48 mln EUR.Presenting confirmation of the responsible persons of AB “Linas” and interim consolidated not audited financial information of nine months of year 2019.AB “Linas” chief of financeEgidijus Mikeliūnas+370 45 506100AttachmentAtskaitomybė 1909 ENG

Continue reading

AB „Linas“ 2019 metų devynių mėnesių neaudituota konsoliduota tarpinė informacija

2019 m. lapkričio 29 d. AB „Linas“ valdyba patvirtino auditorių netikrintas AB „Linas“ 2019 metų devynių mėnesių konsoliduotas tarpines finansines ataskaitas, parengtas pagal ES priimtus Tarptautinius finansinės atskaitomybės standartus.AB „Linas“ Grupės 2019 metų sausio-rugsėjo mėnesių pardavimo pajamos sudarė 9,9 mln. eurų, kai 2018 m. tuo pačiu laikotarpiu – 9,2 mln. eurų.AB „Linas“ įmonių grupės 2019 metų devynių mėnesių pelnas prieš apmokestinimą – 0,13 mln. eurų. 2018 m. to paties laikotarpio Grupės rezultatas – pelnas 0,48 mln. eurų.Pateikiame AB „Linas“ atsakingų asmenų patvirtinimą ir 2019 m. devynių  mėnesių tarpines konsoliduotas neaudituotas finansines ataskaitas.AB „Linas“ finansų vadovasEgidijus Mikeliūnas+370 45 506100PriedasAtskaitomybė 1909 LTU

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.